COPENHAGEN, Denmark, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The International Institute of Infant Sleep (IIISleep) has built a ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced preliminary safety and antitumor data for RMC-9805, ...

Following this exciting showcase, Advanced Care Group is gearing up for its next major event at Arab Health in Dubai, set for January 2025. The company plans to further demonstrate its commitment to ...

An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – ...

To access a live webcast of the update, please use this link. Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and ...

The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today ...

"With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition product to market and ensure that customers and patients in need have ready ...

$16 million upfront with the potential for an additional $16 million upon the exercise in full of warrants ...

CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced it will host a conference call to discuss its Byte Aligner ...

Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator. A webcast of the presentation will be available ...

Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 ...